Accurate Identification of HER2-Positive Patients Is Essential for Superior Outcomes With Trastuzumab Therapy

Nathalie Chorn

ONF 2007, 33(2), 265-272. DOI: 10.1188/06.ONF.265-272

Purpose/Objectives: To review the clinical significance, methods of testing, and outcomes of trastuzumab (Herceptin®) treatment for HER2 gene amplification and HER2 protein overexpression in breast cancer.

Data Sources: Published articles and abstracts, online resources, a clinical handbook, and product information.

Data Synthesis:HER2 gene amplification or HER2 protein overexpression can be found in 20%-25% of breast cancers and is important pathogenic and prognostic information. HER2 also predicts patient response to trastuzumab. Patients with HER2-positive metastatic breast cancer benefit from trastuzumab whether selected by immunohistochemistry, which measures the HER2 protein, or fluorescence in situ hybridization (FISH), which measures the HER2 oncogene. However, patients who are identified accurately as HER2 gene-amplified by FISH derive the greatest benefit.

Conclusions: Accurate testing is crucial for appropriate identification of patients for trastuzumab therapy. FISH is the most reproducible and accurate method.

Implications for Nursing: Education regarding HER2 testing and trastuzumab helps patients to make informed decisions and facilitates active participation in their care as well as enhances dialogue with physicians.

Jump to a section

    References

    Allred, D.C., Harvey, J.M., Berardo, M., & Clark, G.M. (1998). Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Modern Pathology, 11, 155-168.
    Bartlett, J.M., Going, J.J., Mallon, E.A., Watters, A.D., Reeves, J.R., Stanton, P., et al. (2001). Evaluating HER2 amplification and overexpression in breast cancer. Journal of Pathology, 195, 422-428.
    Bast, R.C., Jr., Ravdin, P., Hayes, D.F., Bates, S., Fritsche, H., Jr., Jessup, J.M., et al. (2001). 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. Journal of Clinical Oncology, 19, 1865-1878.
    Berry, D.A., Muss, H.B., Thor, A.D., Dressler, L., Liu, E.T., Broadwater, G., et al. (2000). HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. Journal of Clinical Oncology, 18, 3471-3479.
    Bianco, A., De Laurentiis, M., Carlomagno, C., Gallo, C., Panico, L., & De Placido, S. (2000). HER2 overexpression predicts adjuvant tamoxifen (TAM) failure for early breast cancer (EBC): Complete data at 20 yr of the Naples GUN randomized trial [Abstract 289]. Proceedings of the American Society of Clinical Oncology, 19, 75a.
    Burstein, H.J., Kuter, I., Campos, S.M., Gelman, R.S., Tribou, L., Parker, L.M., et al. (2001). Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. Journal of Clinical Oncology, 19, 2722-2730.
    Carlomagno, C., Perrone, F., Gallo, C., De Laurentiis, M., Lauria, R., Morabito, A., et al. (1996). C-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. Journal of Clinical Oncology, 14, 2702-2708.
    Clinical laboratory assays for HER-2/neu amplification and overexpression: Quality assurance, standardization, and proficiency testing. (2002). Archives of Pathology and Laboratory Medicine, 126, 803-808.
    Cobleigh, M.A., Vogel, C.L., Tripathy, D., Robert, N.J., Scholl, S., Fehrenbacher, L., et al. (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Journal of Clinical Oncology, 17, 2639-2648.
    Coussens, L., Yang-Feng, T.L., Liao, Y.C., Chen, E., Gray, A., McGrath, J., et al. (1985). Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science, 230, 1132-1139.
    Dybdal, N., Leiberman, G., Anderson, S., McCune, B., Bajamonde, A., Cohen, R.L., et al. (2005). Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Research and Treatment, 93, 3-11.
    Esteva, F.J., Valero, V., Booser, D., Guerra, L.T., Murray, J.L., Pusztai, L., et al. (2002). Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. Journal of Clinical Oncology, 20, 1800-1808.
    Fornier, M., Risio, M., Van Poznak, C., & Seidman, A. (2002). HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology, 16, 1340-1352.
    Genentech, Inc. (2000). Herceptin® [trastuzumab] full prescribing information. South San Francisco, CA: Author.
    Gray, J.W., & Pinkel, D. (1992). Molecular cytogenetics in human cancer diagnosis. Cancer, 69(6, Suppl.), 1536-1542.
    Gusterson, B.A., Gelber, R.D., Goldhirsch, A., Price, K.N., Save-Soderborgh, J., Anbazhagan, R., et al. (1992). Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. Journal of Clinical Oncology, 10, 1049-1056.
    Horton, J. (2001). Her2 and trastuzumab in breast cancer. Cancer Control, 8, 103-110.
    Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., & Jain, R.K. (2002). Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature, 416(6878), 279-280.
    Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R.C., Ghafoor, A., et al. (2005). Cancer statistics, 2005. CA: A Cancer Journal for Clinicians, 55, 10-30.
    Kallioniemi, O.P., Kallioniemi, A., Kurisu, W., Thor, A., Chen, L.C., Smith, H.S., et al. (1992). ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proceedings of the National Academy of Sciences of the United States of America, 89, 5321-5325.
    Kim, R., Tanabe, K., Uchida, Y., Osaki, A., & Toge, T. (2002). The role of HER-2 oncoprotein in drug-sensitivity in breast cancer [Review]. Oncology Reports, 9(1), 3-9.
    Mass, R.D., Press, M.F., Anderson, S., Cobleigh, M.A., Vogel, C.L., Dybdal, N., et al. (2005). Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clinical Breast Cancer, 6, 240-246.
    National Comprehensive Cancer Network. (2005). Clinical practice guidelines in oncology: Breast cancer. Retrieved January 20, 2006, from http://www.ncon.org/professionals/physician_gls/PDF/breat.pdf
    Paik, S., Bryant, J., Tan-Chiu, E., Romond, E., Hiller, W., Park, K., et al. (2002). Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. Journal of the National Cancer Institute, 94, 852-854.
    Paik, S., Hazan, R., Fisher, E.R., Sass, R.E., Fisher, B., Redmond, C., et al. (1990). Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer. Journal of Clinical Oncology, 8, 103-112.
    Pauletti, G., Dandekar, S., Rong, H., Ramos, L., Peng, H., Seshadri, R., et al. (2000). Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry. Journal of Clinical Oncology, 18, 3651-3664.
    Pauletti, G., Godolphin, W., Press, M.F., & Slamon, D.J. (1996). Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene, 13, 63-72.
    Pegram, M.D., Lipton, A., Hayes, D.F., Weber, B.L., Baselga, J.M., Tripathy, D., et al. (1998). Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. Journal of Clinical Oncology, 16, 2659-2671.
    Pegram, M.D., & Slamon, D.J. (1999). Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: Evidence for receptor-enhanced chemosensitivity. Seminars in Oncology, 26(4, Suppl. 12). 89-95.
    Perez, E.A., Roche, P.C., Jenkins, R.B., Reynolds, C.A., Halling, K.C., Ingle, J.N., et al. (2002). HER2 testing in patients with breast cancer: Poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clinic Proceedings, 77, 148-154.
    Persons, D.L., Borelli, K.A., & Hsu, P.H. (1997). Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Modern Pathology, 10, 720-727.
    Press, M.F., Bernstein, L., Thomas, P.A., Meisner, L.F., Zhou, J.Y., Ma, Y., et al. (1997). HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. Journal of Clinical Oncology, 15, 2894-2904.
    Press, M.F., Hung, G., Godolphin, W., & Slamon, D.J. (1994). Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. Cancer Research, 54, 2771-2777.
    Press, M.F., Sauter, G., Bernstein, L., Villalobos, I.E., Mirlacher, M., Zhou, J.Y., et al. (2005). Diagnostic evaluation of HER-2/neu as a molecular target: An assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clinical Cancer Research, 11, 6598-6607.
    Press, M.F., Slamon, D.J., Flom, K.J., Park, J., Zhou, J.Y., & Bernstein, L. (2002). Evaluation of HER-2/neu gene amplification and overexpression: Comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. Journal of Clinical Oncology, 20, 3095-3105.
    Ridolfi, R.L., Jamehdor, M.R., & Arber, J.M. (2000). HER-2/neu testing in breast carcinoma: A combined immunohistochemical and fluorescence in situ hybridization approach. Modern Pathology, 13, 866-873.
    Rieger, P.T. (1999). Monoclonal antibodies. In Clinical handbook for biotherapy (pp. 197-238). Sudbury, MA: Jones and Bartlett.
    Robert, N., Leyland-Jones, B., Asmar, L., Belt, R., Ilegbodu, D., Loesch, D., et al. (2002). Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advanced breast cancer. Breast Cancer Research and Treatment, 76(Suppl. 1), S37.
    Roche, P.C., Suman, V.J., Jenkins, R.B., Davidson, N.E., Martino, S., Kaufman, P.A., et al. (2002). Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. Journal of the National Cancer Institute, 94, 855-857.
    Rosenzweig, M.Q., Rust, D., & Hoss, J. (2000). Prognostic information in breast cancer care: Helping patients utilize important information. Clinical Journal of Oncology Nursing, 4, 271-278.
    Schaller, G., Evers, K., Papadopoulos, S., Ebert, A., & Buhler, H. (2001). Current use of HER2 tests. Annals of Oncology, 12(Suppl. 1), S97-S100.
    Sjogren, S., Inganas, M., Lindgren, A., Holmberg, L., & Bergh, J. (1998). Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. Journal of Clinical Oncology, 16, 462-469.
    Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., & McGuire, W.L. (1987). Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-182.
    Slamon, D.J., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Pawlicki, M., et al. (2005). Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Paper presented at the 28th Annual San Antonio Breast Cancer Symposium, San Antonio, TX.
    Slamon, D.J., Godolphin, W., Jones, L.A., Holt, J.A., Wong, S.G., Keith, D.E., et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707-712.
    Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine, 344, 783-792.
    Sliwkowski, M.X., Lofgren, J.A., Lewis, G.D., Hotaling, T.E., Fendly, B.M., & Fox, J.A. (1999). Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Seminars in Oncology, 26(4, Suppl. 12), 60-70.
    Tubbs, R.R., Pettay, J.D., Roche, P.C., Stoler, M.H., Jenkins, R.B., & Grogan, T.M. (2001). Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message. Journal of Clinical Oncology, 19, 2714-2721.
    Vogel, C.L., Cobleigh, M.A., Tripathy, D., Gutheil, J.C., Harris, L.N., Fehrenbacher, L., et al. (2002). Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. Journal of Clinical Oncology, 20, 719-726.
    Vysis Inc. (2000). PathVysion™ HER2 DNA probe kit. Downers Grove, IL: Author.
    Winstanley, J., Cooke, T., Murray, G.D., Platt-Higgins, A., George, W.D., Holt, S., et al. (1991). The long term prognostic significance of c-erbB-2 in primary breast cancer. British Journal of Cancer, 63, 447-450.
    Yamauchi, H., Stearns, V., & Hayes, D.F. (2001). When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. Journal of Clinical Oncology, 19, 2334-2356.